The chemistry of pteridines was always closely related to structure elucidations of newly discovered naturally occurring pterins and lumazines. The buttcrtly pigments xanthopten"n, isoxanthopterin and leu-(oprerin can be regarded as the first mile-stones in this field-which led to the recognition of a new, unusual heterocyclic nucleus called by the late Heinrich Wieland "pteridine".
More deeply colored butterfly pigments are represented by the orange erythropten"n and the violet-blue pterorhodin. The later pigment was originally described by Frederic Gowland Hopkins as an artefact derived from the more common yellow pigments by acid catalysis and oxidation. Interestingly, some time ago it could be shown that pterorhodlin is actually a naturally occurring pigment which has been found in butterflies and various insects. Its unusual physical properties, especially the insolubility in most organic solvents seems to be responsible that only a few investigations regarding the fine structure of this compound have been reported. New results derived from more soluble model substances will be discussed in detail.
The red eye-pigments of the fruit fly Drosophila Pteridines / Vol. 5 / No.1 melanogaster turned out to be a complex mixture of three pairs of enantiomers called drosopten"n, aurodrosopten"n and neodrosopten"n. The proposed structures of drosopterin and its structural analogs will be confirmed by improved NMR-spectra which offer also information regarding the stereochemistry of these pigments. The constitution of aurodrosopterin has recently been elucidated by a synthetic approach deduced from the biogenetic pathway of the pteridines. The structure of neodrosopterin is still open and will therefore be discussed speculatively. The structure of Photinuspterin isolated from the firefly Photinus pyralis was also proven by chemical synthesis applying the approach of homolytic nucleophilic substitution reactions for C-C bond formation. This synthesis will demonstrate the usefullness of radical substitution reactions in the field of 7T-deficient nitrogen heterocycles.
A new pteridine comPound was isolated from green sulfur photosynthetic bacteria, Chlorobium /imicola f thiosulfatophilum NCIB 8327. The structure of this pterin derivative was established to be I' -(erythro-biopterin)-~-N-acetylglucosamine from IH and I3C NMR F AB and thermospray mass spectrometry and chemical cleavage technique. Upon acid hydrolysis of this pterin derivative, equimolar amounts of biopterin and N-acetylglucosamine were produced. Biopterin, one of hydrolytic products, was confirmed by comparing its NMR UV-visible, mass spectrum and its chromatographic behavior with authentic specimen. N-acetylglucosamine was identified by enzymatic hydrolysis experiment as well as NMR and thin layer chromatography. F AB and thermospray mass spectrometry yielded MH + of 441. Periodate oxidation experiments of the intact molecule and its hydrolytic product are consistent with the proposed structure. Differential iodine oxidation experiment showed that in vito oxidation state of this pterin is tetrahydro-form. We propose the trivial name "limuspterin" for this new compound. Heizan Kawamoto I and Wolfgang Pfleiderer IDepartment of Chemistry, Faculty of Science, Okayama University, Okayama 700, Japan and 2Univer-sitat Konstanz, Fakultat ftir Chemie, 78434 Konstanz, Germany In an attempt to explore efficient and versatile glycosid1!tion methods for biopterin and related compounds, we reported N2-(N,N-dimethyl-amino) methy1ene-0'-(2-p-nitrophenylethyl)-biopterin as a useful intermediate 1 • Close comparison of various spectral data with those of the related compounds, however, has led us to revise the structurc of the above intermediate to be the N2,3-protected biopterin (I). Glycosidation of the side chain of I has been studied by employing 1-o-acetyl-2,3,5-tri-o-benzoyl-~ D-ribofuranose as a model donor, as illustrated in the following scheme. Deprotection of the resulting products gives the corresponding 2'-0-(2) and 1',2',-di -o-w-D-ribofuranosy 1 )-biopterin(3). A sensitive and simple reversed-phase ion-pair liquid chromatographic system with fluorimetric detection by post-column sodium nitrite oxidation was established for measuring eleven pterin compounds; 6, 7 , , 6, 7, , 7,8-dihydrobiopterin (BH2)' biopterin (B), 5, 6, 7, ' 7, , 5, 6, 7, 7, , pterin (P) and isoxanthopterin (IX). A linear detector response and the coefficients of variation for these pterins were verified, and the minimum detectable amount was ca. 10-20 pg. The concentrations of the pterin compounds in rat tissues were measured by this method. Furthermore, microdialysis in combination with this sensitive method enables us to measure the levels of endogenous intrastriatal pterin compounds. Therefore, this method will be useful in clinical diagnosis and for basic studies of pterins. In addition, we attempt to measure the levels of R-Bfu and related other pterin compounds in cerebrospinal fluid (CSF) from autistic and neurologically normal children by this direct assay in comparison with the values of total, reduced and oxidized pterins by the Fukushima and Nixon method.
Synthesis of 2' -D-and I' ,2' -Di-D-(~-
A mechanism for the formation of 7-substituted pterins from 4a-hydroxy-5,6,7,8-tetrahydrobiopterin (4a -carbinolamine) , has been recently proposed by our group and by Davis et al. In this study the enzymatic mechanism of tryptophan hydroxylase isolated from mouse mastoma P-815 cells, was studied by HPLC detection of tetrahydrobiopterin oxydation products and 5-hydroxytryptop han formation.
We report in this communication that by incubation of tetrahydrobiopterin with 4a-carbinolamine dehydratase (PCD) free tryptophan hydroxylase (fPH) one mol of 7-biopterin per 2-3 mol of 5-hydroxytryptophan (5-HTP) are formed.
The addition of PCD, an enzyme catalyzing the dehydration of the pterin intermediate 4a-hydroxytetrahydrobiopterin, formed during tryptophan hydroxylation reaction, results in a 3-fold increase of 5-HTP and in the prevention of non-enzymatic 7-biopterin synthesis. It could be demonstrated that tryptophan hydroxylase is inhibited by 7-tetrahydrobiopterin with a K; value of 225 !JM. Our results suggest that the absence of PCD and high 7-biopterin levels in primapterinuric patients can lead to reduced serotonin formation. A new deaminase specific for the quinonoid dihydropterin was purified from the head extracts of Drosophila melanogaster. The enzyme deaminate specifically 6.7,8-quinonoid-dihydropterin derived from H4-pterin and produce 6-hydroxy-7,8-dihydropterin via 7.8-dihydrolumazine. The true substrate of this enzyme was established by the coupled assay with dihydropteridine reductase (DHPR), the effect of antioxidants. and the preincubation experiments.
The specific activity was raised 5,800 fold over that of the crude extracts by conventional purification procedures including 30-60% ammonium sulfate fractionation. gel ftltration, hydrophobic chromatography and chromatofocusing. The enzyme consisted of a single polypeptide chain of 45,700 dalton. The pH and temperature optima for the deamination reaction were pH 7.0 and 50°C respectively. The iso-electric point of the protein was pH 5.5. Some other biochemical characteristics such as heat stability, cation requirements, effect of inhibitors were investigated. The enzyme was enriched in the head and high level of the activity was detected just after eclosion during the developmental stage.
A drosopterin pigment was synthesized nonenzymatically from 6-acetyl-dihydropterin and the deaminated reaction product of the enzyme. The synthesized product was identified as aurodrosopterin by cellulose thin-layer chromatography, and from its NMR and UV spectra. Therefore, this deaminase seems to have the function of supplying one of the precursors, Hrlumazine, in the synthesis of the minor Drosophila eye pigment, aurodrosopterin.
Molecular Cloning of the Gene for GTP Cyclohydrolase I.
Hiroshi lehinose and Toshiharu Nagatsu
Institute for Comprehensive Medical Science, School of Medicine, Fujita Health University, Toyoake, Aichi 470-11, Japan
The conversion of GTP to D-erythro-7,8-dihydroneopterin triphosphate is the first and rate-limiting step in the tetrahydrobiopterin (BH4) biosynthetic pathway, and is catalyzed by GTP cyclohydrolase I. Recently Hatakeyama et al. isolated a cDNA clone encoding rat GTP cyclohydrolase I and reported the nucleotide sequence. We have cloned human and mouse GTP cyclohydrolase I cDNA using the rat cDNA as a probe to examine the genetic regulation of BH4 biosynthesis under various physiological and pathological conditions. Three hundred-thousands of recombinants from a human liver cDNA library was screened through plaque hybridization. Eighteen substantially hybridized clones were isolated, and subcloned into a plasmid vector. These clones were classified into three types according to restriction mapping and sequencing. The cDNA clones were found to diverge at their 3' ends and were designated as hGCH-l, hGCH-2, and hGCH-3.
The coding regions of these clones encoded a protein of 250 amino acid residues in hGCH-l, 213 residues in hGCH-2, and 209 residues in hGCH-3, respectively. The clone, hGCH -1, was comparable to the rat enzyme. and 92.5% of the predicted amino acid sequence was identical with the rat enzyme. In comparison \vith rat sequence, however, it was noted that an additional 9 amino acids at the Nterminus existed in the human sequence.
We also isolated a full-length cDNA clone for GTP cyclohydrolase I from a mouse brain cDNA library. The coding region encoded a protein of 241 amino acid sequence with a calculated molecular mass of 27,014 daltons. The deduced amino acid sequence of mouse GTP cyclohydrolase I was highly homologous to rat (96%) and hGCH-I (89%) enzymes. 6-pyruvoyl-tetrahydropterin-synthase (6PTP-synthase) is one of the key enzymes in the tetrahydrobiopterin (BH4) biosynthetic pathway. 6PTP-synthase deficiency is the most common genetic disease of BH4 metabolism. As an initial step to approach and understand molecular mechanisms of 6PTP-synthase expression, we have amplified 611 base pairs of rat pineal gland 6PTP-synthase cDNA based upon the reverse transcription-polymerase chain reaction (PCR). A 324 base sequence, a portion of PCR-amplified DNA., has been used as a probe for the analysis of 6PTP-synthase mRNA in the various rat tissues by Northern blot and nuclease protection assay. PCR-amplified DNA was cloned into the pGEM-3Z vector in PstI and Aval poly-linker sites. Plasmid DNA was sequenced in both direction to confirm that the amplified-DNA corresponded to that of liver 6PTP-synthase. Consequently, we found 2 different nucleotides between this sequence of amplified DNA and the previously published rat liver 6PTP-synthase cDNA sequence (Inoue, Y., et al., 1991 J. BioI. Chern. 266, 207910-20796) . The nucleotides 368 and 625 of 6PTP-synthase sequence were C and T for PCR-amplified DNA., while T and A for a previously published rat liver cDNA. We investigated the distribution of 6PTP-synthase mRNA in the various rat tissues using the quantitative Tl nuclease protection assay,. 6PTP-synthase mRNA was found to be expressed with equivalent abundance across various rat tissues. 6PTP-synthase mRNA was also found in the brainstem. Additionally, we will present the distribution of 6PTP-synthase mRNA in the rat various brain regions by protection assay and in situ hybridization at the meeting. (Supported by NIH
NS26081)
A Missense Mutation of 6-Pyruvoyl-tetrahydropterin Synthase Deficiency in Japanese Takuji Imamura', Yoshiyuki Okano', Yoshitomo Sawada 2 , Yutaka Hase 3 , Toshiaki Oura 4 , Gen Isshiki' and Haruo Shintaku' 'Dept. of Pediatr., Osaka City University Medical School, Osaka 545, Japan, and 2Dept. of Pediatr., Osaka City General Hospital, Osaka 534, Japan, and 3Dept. of Pediatr., Kita Citizens' Hospital, Osaka 554, Japan, and 40saka Municipal Rehabilitation Center for the Disabled, Osaka 547, Japan.
Tetrahydrobiopterin (B~) is a cofactor of phenylalanine hydroxylase, tyrosine hydroxylase and tryptophan hydroxylase. BH4 deficiency impairs the biosynthesis of neurotransmitters. Patients with BH4 deficiency will go on to develop progressive neurologic deterioration. We identified human PTPS cDNA and found a mutation of 6-pyruvoyl-tetrahydropterin synthase (PTPS) gene in three Japanese patients with PTPS deficiency. Parents of two patients were unrelated and parent of one patient were second cousin.
The rat PTPS cDNA cloned in PUCl8 was labelled with 32p, and used for screening a Agtll-vectorderived human fibroblast cDNA library. The sequence of human PTPS cDNA was the same as the published sequence in amino acid coding region. Total RNA was isolated from lymphoblastoid cells transformed with Epstein-Barr virus by acid thiocyanate guanidine method. PTPS cDNA was amplified from the total RNA by RT-PCR method, and was directly sequenced using Dynabeads™ (Dynal co. Ltd.). The missense mutation was a C to T transition in the PTPS gene, resulting in the substitution of Pro by Ser at the codon 87 (P87S). This P87S mutation was found as homozygote in two patients and as a compound heterozygote in one patient. This P87S mutation is found to be a conserved region in the homologous enzyme from salmon, rat and human, and is an important region of PTPS activity.
Are the B~-Generation Enzymes Regulated By CaZ+ Dependent Phosphorylation?
Setsuko Katoh', Terumi Sueoka', Yoshimi Yamamot0 2 and Susumu Y. Takahashi Dentistry, Sakado Saitama 35(4)2, Japan, 2Dept. of Biology, Faculty of Liberal Arts, Yamaguchi University, Yamaguchi 753, Japan It was known that tetrahydrobiopterin (BH4)-requiring enzymes of aromatic amino acid hydroxylases and nitric oxide synthase are regulated in their functions by phsophorylation with various protein kinases. As for the BH4-generating enzymes, phosphorylation of them by protein kinases have been found. Three NAD(P)H-oxidoreductases are confirmed for the direct supply of BH4: sepiapterin reductase (SPR; the terminal enzyme in the BH4 biosynthetic pathway), dihydropteridine reductase (DHPR; the enzyme regenerating B~ from quinonoid dihydrobiopterin formed in the hydroxylation system), and dihydrofolate reductase (DHFR; the enzyme regeneration BH4 from 7,8-dihydrobiopterin formed spontaneously from quinonoid dihydrobiopterin). Purified rat SPR, sheep DHPR, and bovine DHFR were incubated with [y_32PJ ATP in the system of protein kinases and 32p incorporation into the subunit of each enzyme was analyzed by autoradiography after SDS-PAGE. Phosphorylation of SPR was significantly observed by Ca2+ /ca1modulin dependent protein kanase II (CaM-Kll) and protein kinase C (PKC) while it was neither by cAMP-dependent protein kinase nor cGMP-dependent protein kinase. DHPR, the main enzyme for regenerating BH4, was phosphorylated by CaM-KII. No radioactivity into DHFR was detected by all protein kinases examined. SPR and DHPR were as good substrates as smooth muscle myosin light chain for C a!vf-KII in the initial rate of phosphorylation. Maximal incorporation of 32p into SPR by CaM-KII and PKC were 3.05 and 0.74 mole/mole subunit., respectively. The value by CaM-KII coincided with the number of site consensus sequence [R-X-X-S*J for CaM-KII found in the subunit of rat SPR. SPR was modified in its kinetical properties by phosphorylation by either CaM-KII or PKC. These results were the first finding of phosphorylated enzymes in the BH4-generating system. These suggest that BH 4 formation is controlled by Ca2+ ion in the cell through phosphorylation of B~-generating enzymes by Ca2+ -dependent protein kinases of CaM-KII and PKC.
A. Methyl terahydrofolate (MTHF) and SAM are known to be important methyl donors in brain (Hirata and Axelrod, Science 1980; 209: 1082) . In view of to a close relationship between the methylation defect in brain and the neurological abnormalities (Surtees et ai., Lancet 1991; 338: 1550) , we have developed a simple and sensitive enzymatic method to deermine the SAM concentration using (C-14) MTHF, methyl-B 12 , homocysteine and partially purified E. coli methionine synthetase. The reaction product., (C-14) methionine was separated from the substrate (C-14) MTHF on a mini Dowex 2 column. The reaction was linear up to a SAM concentration of 0.4 jJIllollL. Various forms of folates were measured by the microbiological assay using L casei and S. faecalis (Tamura and Freeberg, Chemistry and Biology of Pteridines 1989 Pteridines , 1990 p. 740) . In CSF MTHF was the major form consisting of about 90-100% of total folates (14-25 ng/mL). The SAM concentration in CSF ranged from 110 to 420 nmollL (1-10 years of age, n= 14). These values are comparable to those by other methods such as HPLC (Surtees and Hyland, Anal Biochem 1989; 53 : 569 Christensen and Rosenblatt showed that fibroblast cell lines from MR deficiency were not able to grow in a medium containing homocysteine, vitamin BI2 and MTHF unless methionine was supplemented. This suggests an ineffectiveness of MTHF in MR deficiency. In their studies, however, a relatively high amount of homocysteine (200 jJIllollL) was used, which can eventually be converted to S-adenosyl homocysteine (SAH), a compettttve inhibitor of SAM for various methylation reactions. In order to investigate the true effect of MTHF, the cell growth study has been performed with various amounts of homocysteine, SAM and MTHF. The MR deficient ':ell ' line (KE) was from a female patient with the -('\'ere clinical form. Contrary to the above experi1ent the MR deficient cells started to grow some-., hat with a medium containing 20 Ilmol/ L homo-: steine, MTHF and methyl-cobalamine. The best ;rowth, however, was achieved in the medium con-:_: ining 500 nmol/L 6S-MTHF and 2 Ilmol/L SAM. This suggests again the toxic effect of high amounts ' f homocysteine in the medium and SAM deficien-.:y in the cells probably due to prolonged methio-:-. ine deficiency. This further indicates that an appli-_.ltion of MTHF possibly in combination with SAM -:1ay be beneficial to patients with MR deficiency. In man, unequivocal evidence exists of deficien-.:ies in monoamine neurotransmission that are the Ji rect result of genetic defects in BH4 biosynthetic )r regenerative processes. Individuals amicted with ~hese genetic diseases are typically detected at birth hy the diagnosis of hyperphenylalanemia. With the exception of the "peripheral" form of BH4 deficien-. . ::y. in these patients severe neurological and cognitive dysfunctions typically occur later in development despite dietary control of phenylalanine intake. To date, genetic diseases that increase rather . than decrease levels of BH4 have not been observed in the clinic. Although rarely if ever referred to in the neurology and mental health literature, the existence of these genetic mutations in BH4 metabolism that interfere with normal monoamine biosynthesis would seem to support theories that hypothesize abnormal monoamine synthesis as the cause of numerous neuropsychiatric diseases. Because these diseases are believed to involve specific popUlations of neurons, however, for any such theory to include a role for aberrant BH4 metabolism would reguire that alterations in BH4 metabolism also be restricted to specific populations of neurons. This reguirement would seemingly go against the characterization of BH4 as simply an "interested bystander" in neurotransmitter biosynthesis. Our presentation will attempt to describe and integrate clinical and basic research that support the hypothesis that the metabolism and regulatory control of BH4 are normally heterogeneous across different populations of monoamine-containing neurons. Based upon this hypothesis, ther is now support for the idea that certain neuropsychiatric illnesses, which are though to be the result (at least in part) of altered monoamine metabolism, might find their roots in an abnormal metabolism of BH4 within specific monoaminergic cell groups. Such a specific dysfunction might not be apparent in the rest of the brain or peripheral nervous system, thereby being difficult to detect.
Role of 4a-Hydroxytetrahydropterin Dehydratase/ DCoH
June E. Ayling and Steven W . Bailey Department of Pharmacology, University of South Alabama, Mobile, AL 36688, USA.
The recent discovery that 4a-hydroxytetrahydropterin dehydratase has the same sequence as the hepatic dimerization cofactor, DCoH, (1, 2) has raised the question of whether both activities of this protein have physiological significance. Dehydration of 4a-hydroxytetrahydrobiopterin, the cofactor product of the reactions of the aromatic amino acid hydroxylases, is essential for the regeneration of active cofactor. However, dehydration occurs spontaneously in the absence of dehydratase. The non-enzymatic rates of dehydration of 4a-hydroxytetrahydropterins have been studied under a variety of conditions and compared with the rates of the enzyme catalyzed reactions. This was accomplished using synthetically produced 4a-hydroxytetrahydropterins. The results indicate that under physiological conditions the rate of non-enzymatic dehydration is too slow to maintain cofactor in the active form. Without the action of the dehydratase, 4a-hydroxytetrahydrobiopterin would accumulate in the liver and its dehydration would become rate limiting for the reaction of phenylalanine hydroxylase. Genetic factors also are consistent with a role for the dehydratase/DCoH which is necessary for phenylalanine metabolism. Following the procedure reported by Bailey and Ayling [Bailey, S. W., Boerth, S. R , Dillard, S. R , and Ayling, J. E., (1993) in "Chemistry a nd Biology of Pteridines and Folates", (Ayling et al. eds.) Plenum Press, New York, pp. 47-54J we have prepared the 4a-hydrates of quinoid 6,6-dimethyl-and 6-(R,S)-methyldihydropterin. The decay rate of these compounds to the corresponding quinoid dihydropterin is enhanced in the presence of recombinant human pterin-4a-carbinolamine dehydratase (PCD, formerly named phenylalanine hydroxylase stimulating protein, PHS). The kinetic parameters of this reaction have been investigated in some detail. PCD was found to bind several synthetic pterins, which thus inhibit catalytic activity.
Regulation of Tryptophan Hydroxylase in Serotonin Producing Cells
H:ro:-uki Ha s~ga wa and Kazuya Oguro D~p a rtm~nt of Bioscience, The Nishi-Tokyo Univer5i ty. Yamanas hi 409, Japan Tryptophan hydroxyl ase is th e key enzyme in the biosynthesis of serotonin in serotonergic organs. The cellular mechanism that regulates activity of this enzyme has been poorly understood, we previously presented data which demonstrated that the intracellular activity of this enzyme is limited by the supply of ferrous iron in the cell. Its full potential activity can be measured in cell free extracts when sufficient iron is supplied in the presence of dithiothreitol whereas the intracellular activity can be measured in cultured cells by accumulation of 5HTP in the presence of NSD-1015, an inhibitor of aromatic-Lamino acid decarboxylase. A rat basophilic leukemia cell line, RBL2H3, retains m ast-cell-like characteriPteridincs / Vol. 5 / No. I stics such as being able to respond to antigen-IgE stimulation by releasing vasoactive substances including serotonin and histamine. Tryptophan hydroxylase activity of this cell, however. is much lower than that of mouse tumor derived cell-lines, mastocytoma P-815 and FMA3, even when their full potential activity is measured in vitro, indicating that another mechanism dominates over the modulation of the enzyme activity by the iron supply. W e considered that these latter cells of a long established culture line, had lost the ability to maintain the enzyme at a functional level. We focused on tryptophan hydroxylase turnover, that is, the balance between biosynthesis and degradation of the enzyme. By incubating RBL2H3 cells in culture with cycloheximide (1 J.1g/rnl), the enzyme dropped to half its normal level within 20 min and to less than 10% by 60 min. After washing the above reagent out of the medium, the enzyme level of the cell culture immediately began to rise. On the other hand, FAMA3 cells which maintain a high level of the enzyme did not undergo a rapid decrease in the presence of cycloheximide. These results indicate that rapid degradation of tryptophan hydroxylase is balanced by synthesis of the enzyme in RBL2H3 cells. Tetrahydrobiopterin (6R-BH4) is the essential ratelimiting cofactor for tyrosine and tryptophan hydroxylases, the rate-limiting enzymes in catecholamine and serotonin synthesis, respectively. BH4 is also required for the proliferation of cultured murine erythroleukemia cells. We tested the effects of BH4 on the proliferation of other cell types including cultured rat pheochromocytoma (PCI2) cells, rat neuroblastoma NIE1l5 cells, and human SV-40 transformed fibroblasts GM0637 cells. Methodologies used to monitor cellular proliferation included: 1) cell counting with the use of a hemocytometer and trypan blue exclusion or a Coulter counter, 2) quantitation of DNA synthesis by 3H-thymidine incorpor-ation, 3) monitoring of live cells by the use of an enzymatic color formation assay, and 4) fluorometric determination of DNA. A variety of methods for monitoring proliferation was necessary, since certain :nethods were adversely affected by various drug :reatments. Results are presented with a comparison )f methods used. Sepiapterin, dihydrobiopterin, nerve growth factor, epidermal growth factor and iibroblast growth factor were used to elevate intracellular BH4 levels, whereas 2,4-diamino-hydroxypyrimidine, N-acetyl-serotonin and methotrexate were Jsed to inhibit intracellular BH 4 • Preliminary results 'uggest that elevating intracellular BH4 can stimulate :,roliferation of various cell lines. Inhibitors of BH4 '\ nthesis decrease cellular proliferation rates. The -:1echanism of action by whcih intracellular BH4 in-.~ uences cell proliferation will be addressed. Tetrahydrobiopterin (BH4) is the naturally occurring cofactor for tyrosine hydroxylase (fH) and try-;,tophan hydroxylase (fPH), which are the initial Jnd rate-limiting enzymes in catecholamine (CA) ,lOd serotonin (5-HT) synthesis, respectively. Genetic jeficiencies in BH4 biosynthesis occur in newborns (atypical PKU), and altered BH 4 -and CA-related gene expression may be involved in several neuropsychiatric illnesses. Increased intracellular BH4 concentrations elevate both TH and TPH activities, whereas inhibition of BH4 synthesis causes a reduction in CA and 5-HT levels. Previous results using cultured pheochromocytoma (PCI2) cells have shown that nerve growth factor (NGF), interferongamma (lFN--r) and vasoactive intestinal polypeptide (VIP) elevate the activities of both TH and GTPcyclohydrolase (the first and rate-limiting enzyme in BH4 biosynthesis) in vitro following 24 hour exposures in culture. Cycloheximide and actinomycin-D were used in this study to inhibit translation and transcription: respectively, in PCl2 cells treated with NGF, IFN--r, or VIP. to further characterize the co-induction mechanism of GTP-cyclohydrolase and TH, the c-AMP analogues Sp-cAMP (a cAMP agonist) and Rp-cAMP (antagonist) were used alone or in combination with NGF, IFN--r, or YIP. Phorbol-12-myristate-13-acetate (PMA) was used to activate protein kinase C (PKC) and sphingosine was used to inhibit PKC. K252a was used to selectively inhibit the NGF response. Preliminary results suggest that the induction of GTP-cyclohydrolase and TH in vitro activities require active DNA transcription. Furthermore, it seems that both TH and GTPcyclohydrolase are induced by elevating intracellular cAMP levels. The involvement of PKC-dependent mechanisms in the induction of TH and CTP-cyclohydrolase gene expression is still unclear and will be addressed in further studies. 6R-L-erythro-5,6,7,8-Tetrahydrobiopterin (6R-BH4) is a natural cofactor for aromatic L-amino acid hydroxylases and also a cofactor for nitric oxide (NO) synthase. In our recent study using in vivo brain microdialysis, we showed that 6R-BH4 stimulates release of monoamine neurotransmitters such as dopamine (DA), noradrenaline and 5-hydroxytryptamine in vivo independently of the cofactor activities 12. Additionally, 6R-BH 4 was found to indirectly stimulate release of non-monoamine neurotransmitters such as acetylcholine and glutamate via monoaminergic systems 3 .4's. To further characterize the releasing action of 6R-BH4, we attempted to reproduce the effects of 6R-BH 4 in vitro using the superfusion system of rat striatal slices.
Application of 6R-BH4 to the perfusing fluid up to 1 mM had little effect on the spontaneous [ 3HJ DA overflow from the striatal slices prelabelled with [3HJDA. In contrast, high K + -evoked [ 3HJDA overflow was enhanced in a concentration-dependent manner. Biopterin (an oxidized form of 6R-BH4) and other reducing agents such as ascorbic acid and cysteine were without effect. The enhancement by 6R-BH 4 of high K + -evoked [3HJDA overflow was not suppressed by tetrodotoxin, a blocker of voltagedependent Na + channels, but it was abolished after removal of Ca2+ from the perfusing fluid. The enhan-cement was unaffected by either NG-nitro-L-arginine ( Recently, Koshimura et al. reported that 6R-tetrahydrobiopterin (R-THBP) increases dopamine outputs in rat striatal dialysate beside its cofactor role. We have extended the role of R-THBP in the regulation of neurotransmitter release by finding that R-THBP perfusion increased not only dopamine but also serOlLlnin. glutamate and GABA outputs in dialysate ~I t rat striatum and frontal cortex. These effects of R-THBP on dopamine and glutamate outputs in the striatum were quite similar to those of the dopamine antagonists (haloperidol, and sulpiride), suggesting that R-THBP has an antagonistic action on dopamine O 2 receptor. On the other hand, our electrophysiological study showed the dissociation betWeen the actions of D 2 antagonists and R-THBP in J opaminergic signal transmission. Unlike O 2 antJi'On isls. the perfusion of R-THBP did not affect :'1:.: ,triatal evoked by the electrical stimulation of ::-:~ -ubtantia nigra. In this study, we attempted to · _:-".1-:"'r -:haracterize the action of R-THBP using LY ted every 10 min. HPLC with an electrochemical detector was used for the analysis. Following the pretreatment with 100 /-lM LY171555 for 2.0 hour, low dose or R-THBP or vehicle was co-perfused with LY171555 for 30 min. We have developed a new HPLC system which has about 5 times higher sensitivity in measuring dopamine than the previous system. Thus, it is possible, in the present experiments, to reduce the dose of R-THBP and to shorten the sampling time. First, dopamine outputs in striatal dialysate were confirmed to be increased significantly by perfusion of 500 !-lM R-THBP within 20 min. The peak value was 2 times larger than the basal value (basal level; 12.6± 2.7 pg/l0 min, p<O.OI, n = 4). The output was found to be returned to basal level within 10 min after the cessation of R-THBP perfusion. Secondly, perfusion of 100 /-lM LY171555 for 2.5 hour was found to decrease the basal output of dopamine upto 30%. Finally, we found that the perfusion of 100 !-lM LY171555 suppressed the effect of R-THBP on dopamine output. Thus, function of O 2 receptor is probably involved in enhancing dopamine output by R-THBP perfusion. 6, 7, is known as a cofactor for aromatic amino acid hydroxylases and for nitric oxide (NO) synthase, Recently we have shown that 6R-BH4 acts from the outside of the cell to enhance release of monoamine neurotransmitters independently of its cofactor activities 12.3.4. Here, to clarify the mechanism of action of 6R-BH4, we examined the effects of 6R-BH4 on voltage-activated Ca2+ channel currents in neurons of the rat dorsal motor nucleus of vagus using whole-cell voltage-clamp technique. The experiments were performed under conditions that selectively permit the presence of Ca2+ channel currents. By applying depolarizing test pulses (100 ms) from a holding potential of -90 m V to command potentials in the range of -80 to + 10 mY, two distinct components of Ca 2 + currents were identified in the neurons. Command potentials of -60 to -20 mVevo-ked a rapidly inactivating inward current of small amplitude. This current was sensitive to w-conotoxin but resistant to Cd 2 + and nicardipine. At command potentials of -20 m V or greater, a slowly inactivating inward current of relatively large amplitude was evoked in addition to the rapidly inactivating inward current. This current was sensitive to w-conotoxin and Cd2+, but was resistant to nicardipine. The data are consistent with the characteristics of T-type and N-type Ca2+ channel currents, respectively. Application of 6R-BH4 in the !JM range to the bath solution suppressed the T-type channel current but enhanced the N-type channel current. 6S-BH4, a diastereoisomer of 6R-BH4, had no effect on the T-type channel but it had the same stimulatory effect on the N-type channel as 6R-BH 4 • Administration of sodium nitroprusside, an NO generator, was without effect on these two types of Ca2+ currents. These results indicate that 6R-BH4 has direct modulating effects on Ca 2 + channels, which differ depending on subtypes of Ca2+ channel.
J. Koshimura K et al., J Neurochem. 54. 1391 K et al., J Neurochem. 54. -1397 K et al., J Neurochem. 54. (1990 
"-yo 101 , Japan
It is well known that the functional architecture of the visual cortex is not complete at birth but undergoes continuous deVelopment during a postnatal period toward its maturity. By a brief period of monocular deprivation during so-called sen sitive period, many originally binocular cells in the visual cortex lose their functional connectivity with the deprived eye (ocular dominance, 00, plasticity) . The 00 plasticity is absent in the visual cortex of adult cats outside the sensitive period. It is, therefore, crucial to develop a non-invasive method to increase the level of the 00 plasticity in aplastic visual cortex of adult cats for considering a remedy for amblyopia, a developmental anomaly of spatial vision. We have hypothesized a regulatory role of the central noradrenergic (NAergic) system in the 00 plasticity. Previously, activation of the central NAergic system either by direct infusion of the agonist into the visual cortex or electrical stimulation of the locus coeruleus was found to enhance the 00 plasticity. In the present study, we have examined effects of L-lhreo-3,4-dihydroxyphenylserine (L-threo-DOPS) on 00 plasticity. L-threo-DOPS is one of four stereoisomers of the synthetic neutral amino acid 3,4-dihydroxyphenylserine, and this compound administered peripherally is thought to be converted to NA by the central aromatic amino acid decarboxylase. We found that significant changes in 00 distribution is inducible even in juvenile cats outside th e sensitive period by combining monocular deprivation with L-threo-DOPS administration (200 mg/day, per os) for one month. We also noticed that the peripheral administration of L-threo-DOPS enhanced NA output in the visual cortex. In microdialysis experiments, the NA output was found to be increased more than twice the basal value (n = 5) by the administration of L-lhreo-DOPS. Interestingly, the basal output of NA from the visual cortex was found to be disappeared by the perfusion of 10 IJ.M NSD-1015, an inhibitor of aromatic L-amino acid decarboxylase. These results suggested that the total biosynthetic pathway for NA is involved in the regulation and should be considered to develop the novel way for modulating the 00 plasticity. We have previously shown that the perfusion of 6R-tetrahydrobiopterin (R-THBP) significantly increased NA outputs in separate series of microdialysis experiments. It is necessary and interesting, therefore, to study effects of R-THBP on 00 plasticity either by single injection or co-administration with L-lhreo-OOPS.
Cyclic AMP Inhibition of Catecholamine Uptake by Rat Clonal Pheochromocytoma
Satoshi Onozawa, Nobuo Nakanishi, Reiko Matsumoto, Ichino Ohshiro, Akiyoshi Isono, Hiroyuki Hasegawa* and Shozo Yamada Dept. of Biochem., Meikai Univ. Sch. of Dentistry, Sakado, Saitama 350-02, Japan, and *Dept. of Bioscience, Nishi-Tokyo Univ., Uenohara, Yamanashi 409-01 , Japan.
Dibutyryl cAMP (dBcAMP) stimulates dopa production but decreases cellular dopamine (DA) in pheochromocytoma PCl2h cells, a subclone of PC 12. This decrease was accompanied by an increase in the medium DA content, and the sum total of DA of cells and the medium in dBcAMP-treated culture was about 1.5-2 fold over the control culture. Therefore, we have examined the effect of dBcAMP on processes regarding to translocation of the amine. dBcAMP alone did not induce the exocytotic release of endogenous DA nor of norepinephrine (NE) exogenously loaded into secretory vesicles of the cells. dBcAMP, however, inhibited the uptake of NE added into the medium by PC12h and PC12 cells. The inhibition of NE uptake by dBcAMP became clearly detectable only after a certain amount of NE was accumulated inside the cells, and such inhibition profile of dBcAMP was similar to that of reserpine but not of nomifensine. The same results were obtained with forskolin and cholera toxin which are known to elevate intracellular cAMP level. These results strongly suggest that cAMP inhibits catecholamine transport though the secretory vesicle membranes. cAMP virtually decreased the cellular DA content probably by distrubing the amine storage function of the cells, though it enhanced the synthesis of both DO and DA in the cytosolic compartment.
Regulation by Cyclic AMP of Vesicular Transport and Extracellular Level of Monoamine
Nobuo Nakanishi, Sstoshi Onozawa, Reiko Matsumoto, !chino Ohshiro, Masayuki Hara, Hiroyuki Hasegawa*, and Shozo Yamada Dept. of Biochem .. Meikai Univ. Sch. of Dentistry, Sakado. Saitama 350-02. Japan, and *Dept. of Bioscience. Nishi-Tokyo Univ., Uenohara, Yamanashi -+09-()1. Japan
In pheochromocytoma, treatment of the cells with dibutyryl cAMP (dBcAMP), forskolin, or cholera toxin greatly increased the extracellular dopamine level though it decreased its cellular content. We have found that inhibition of amine transport process by cAMP is a key to understand this phenomenon. Results of the norepinephrine uptake experiments by intact PCl2h and PCl2 cells suggested the vesicular transport step as a target of cAMP action. In order to elucidate the mechanism of this cAMP effect, an assay system specific to vesicular monoamine uptake was developed to be applicable to PCl2 cells by permeabilizing their plasma membranes with digitonin. The permeabilized cells retained the ability to uptake exogenous serotonin (SHT) in an ATP-dependent manner. The ATP-dependent 5HT uptake was decreased to about 50% of the control value when the intact cells were incubated with Pteridines I Vol. 5 I No. I dBcAMP for 30 min prior to the digitonin-permeabilization. An addition of dBcAMP into the assay mixture for 5HT uptake by the permeabilized cells, however, gave no significant change in SHT uptake. The results indicated that the inhibitory effect of dBcAMP on vesicular amine transport was mediated by some process which requires membrane integrity and/or some cytosolic component(s). Thus cAMP regulates the intra-and extracellular catecholamine level not only by stimulating its synthesis but also by modulating the vesicular amine transport.
Drug Therapy of Autism: From the Course of Clinical Trials of R-tetrahydrobiopterin
Yoshibumi Nakane
Dept. of Neuropsychiatry, Nagasaki University School of Medicine
In recent international classifications of diseases, infantile autism has become the most typical pervasive developmental disorder among psychiatric disorders in childhood. However, although many · biological hypotheses have been suggested, they are not fully accepted by researchers interested in the disease. Particularly, in the field of neurochemical study, opinions differ greatly in how the changes in brain serotonin level should be judged according to a high blood serotonin level, and when .drug therapy is conducted according to individual ' judgment, as a result completely opposite treatment is tried in patients. The speaker and his colleagues have been examining the effect of pimozide, one of antipsychotics and pentoxifYlline, one of xanthine derivative compound which is claimed to improve syndrome with cerebrovascular insufficiency, and in the last 10 years have been conducting drug therapy from the viewpoint that serotonin turnover in the brain decreases as a blood serotonin level rises, prescribing R-tetrahydrobiopterin which assists the action of hydroxylases such as serotonin and dopamine for autistic children. This study started in 1984 and R-THBP was prescribed for 294 patients including 41 patients in a double-blind, and marked or moderate improvement was seen in 52.2% of the patients. Symptoms in which improvement was observed were major ones for autism and the drug was most effective for "sociability and human relation including symptoms in communication, play, adaptability to new situation' , followed by 'symptoms in speech and language". None of the sideeffects of the drug was severe enough to discontinue the clinical use of the drug.
In 1991, large-scale double blind trials started again to confirm the effectiveness and safety of the drug and decide and optimum dosage. In the trials, 36 institutions where they actively treat autistic children participated in Japan and the total number of subjects was about 220. The subjects were randomly divided into three groups, one with high dosage of R-THBP, one with low dosage of R-THBP and one with inactive placebo.
The trials finished in September 1993, and on November the key for the double-blind was opened. As a result, no significant differences were observed among the three groups. It means the effectiveness of the drug was not confirmed in the trials. At the moment we are still very much disappointed at the results and have not studied the results thoroughly yet. However, we fully realize it difficult to judge the effect of drug therapy for psychiatric disorders in childhood, and in the presentation the speaker will discuss the results in detail. The turnover of the neurotransmitter amines dopamine and serotonin within the brains of Rhesus monkeys and humans has been assessed in vivo by use of Positron Emission Tomography (PET) and the endogenous 3,4-dihydroxy-L-phenylalanine (DOPA), 5-hydroxy-L-tryptophan (5HTP) and an analogue tracer 6-Fluoro-3,4-dihydroxy-L-phenylalanine (FDOPA) all specifically labelled with IIC (Tin = 20.3 min) in the carboxylic or the f3-position of the respective amino acids. This approach opens up the possibility of testing in an non-invasive way of metabolic fate of the label in the PET-tracer.
Pet-Tracers for Non-invasive Assessment of Dopamine and Serotonin Turnover in vivo
By performing repetetive studies using these . PET-tracers in a multi-tracer protocol (repeating studies every 90-120 min using 1IC) and by varying the pharmacological perturbations, n'ew information can be obtained from the PET-studies. This information can for example reflect amino acid transport, vanattons in the physiological conditions with regard to the endogenous activity of enzymes, cofactors such as tetrahydrobiopterin, and various pools of compounds of interest.
In such PET studies we have shown that depending on the position of the radiolabel, the kinetics obtained from the PET-measurements will either directly correlate to the neurotransmitter amine formation or to the labelled carbon dioxide formation as a consequence of the. aromatic L-amino acid decarboxylase reaction in the neurons. In other presentations during this symposium the combined effect of tyrosine and tetrahydrobiopterin on the turnover of dopamine (Tsukada et al.) , the effect of tetrahydrobiopterin treatment on autistic children (Watanabe et al.) , and the regulatory effect on pyridoxin or vitamine B6 (Hertvig et aZ.) all by using the precursor amino acid labelled with IIC in the f3-position are obtaining new information in non-invasive studies.
In this presentation an evaluation of the analogue tracer 6-Fluoro-3,4-dihydroxy-L-phenylalanine (FDOPA) labelled with IIC as compared with 3,4-dihydroxy-L-phenylalanine (DOPA) will be given. Aromatic amino decarboxylase (AADC) catalyzes the decarboxylation of a wide range of amino acids including 5-hydroxy-L-tryptophan (5-HTP) and L-DOPA. AADC is present in the brain in far greater excess than hydroxylase enzymes and therfore AADC is supposed not to be rate-limiting for monoamine synthesis and is assumed not to be modulated by neuronal activity. Recent studies using positron emission tomography, PET have disputed this statement and modulation of the enzyme is possible by treatment with co-factors for the enzyme but also shown in different pathological conditions. PET has made possible the quantitation of the selective cumulation in the brain of 5-HTP and L-DOPA radio- Scand 85: 166-173, 1992) . Studies in Rhesus monkeys have shown a capacity limited utilization in the striatum as seen as lower decarboxylation rate for both radiolabelled substrates when various specific radioactivities were administered (Hartvig et al. J Neural Transm. In press 1993). The capacity limitation was more pronounced for 5-HTP with a lowered rate seen with an amino acid load ten times less as compared to that seen for L-DOPA. A modulation of the AADC is obvious in different pathological conditions. In patients with major depression, an increased serotonin synthesis rate was measured in the medial prefrontal cortical regions (Agren et al. Depression 1: 71-81, 1993 ). Higher dopamine synthesis rate has been measured in Parkinsonian patients with fluctuating symptoms as compared to the rate measured in non-fluctuating disease (redroff et al. Acta Neurol Scand 85 : 95-102, 1992) . A possible coupling between dopamine release and modulation of AADC activity has also been demonstrated with PET as 6R-erythro-5,6,7,8-tetrahydrobiopterin, a cofactor for tyrosine hydroxylase as well as an inducer of dopamine release, elevated the rate constant for striatal decarboxylation of L-DOPA (Watanabe et at. : Tsukada et al. This symposium). A similar effect of 6R-erythro-5,6,7.8-tetrahydrobiopterin was not seen on 5-HTP utilization and other mechanisms were considered to enhance serotonin synthesis rate. Pyridoxin has an important regulatory role as cofactor for the decarboxylation enzyme and hence dopamine and serotonin synthesis rate. Pretreatment of monkeys with 10 mg/kg with pyridoxin phosphate increased the synthesis rate by 15 to 60% for both dopamine and serotonin. Different endogenous levels of pyridoxin may explain the varying effect of supplement vitamin B 6 . Pyridoxin endogenous levels are supposed to be dependent on dietary intake as well as endogenous estrogen concentrations. In conclusion, these possibilities for regulation of the decarboxylase enzyme give new insight into different disease states, and open up for new treatment strategies in diseases characterized by insufficient neurotransmitter supply.
Effect of 6R-L- 6, 7, The effects of 6R-L-erythro-5,6,7,8-tetrahydrobiopterin (6R-BH4) and/or L-tyrosine loading on turnover of dopamine in rat and monkey striatum were evaluated using L-[!3-IIC]DOPA. By monitoring with microdialysis, the increase in the radioactivity fractions of [IIC] dopamine and [IIC] HVA in rat striatal extracellular fluid (ECF) induced by 6R-BH4 (50 mg/kg) was further enhanced by the continuous infusion of tyrosine at a relatively low dose (1.0 /lmol/min/kg). These results reflected the elevation of the concentrations of endogenous dopamine and HV A. This dose of tyrosine alone did not induce the elevation of dopamine and HV A concentrations in ECF. The measurement of DOPA accumulation during the perfusion of NSD 1015, a centrally active L-aromatic amino acid decarboxylase inhibitor, suggested that the enhancement of dopamine concentration in ECF induced by tyrosine infusion and 6R-BH4 might be attributable to an increase in tyrosine hydroxylase activity in striatum. In further experiments, the effect of 6R-BH4 and/or tyrosine on the regional brain kinetics of L-[f3-
Il C] DOPA was measured in R.hesus monkeys using positron emission tomography (PET). The striatal utilization of L-[f3-II C]DOPA was calculated using a graphical method applying cerebellum as a reference region. The rate constant (K3 value) for the utilization in the stria tum of control monkey was 0.011 + / -0.00 1 (n = 10), and tyrosine infusion (1.0 f./mol/min/kg) itself .did not affect K3 value. The injection of 6R-BH4 (20 mg/kg) alone induced the elevation of K3 value (120% of control). 6R-BH 4 and tyrosine infusion resulted in a further elevation of K3 value by 160% of control. These results suggest that tyrosine supplement would contribute to the therapeutic effect of 6R-BH Suppliment therapy of 6R-Tetrahydrobiopterin (R-THBP) has been shown to improve the CNS symptoms of atypical phenylketonuria, a certain type of Parkinson's disease, and some types of infantile autism. In the course of the studies on the molecular mechanisms of such a therapeutic effect of R-THBP, we recently found the direct effect of R-THBP on the release of neurotransmitter amines, namely, dopamine, serotonin, and norepinephrine. Furthermore, the site of initial action of R-THBP was supposed to be a presynaptic dopamine receptor which is involved in regulation of dopamine release and subtyped to be D2 or D 3 receptor. Actually, R-THBP inhibits dopamine D2 receptor binding in the synaptosomal fraction prepared from rat striatum (1). By using noninvasive method, positron emission tomography (PET), and rhesus monkey, we succeeded to demon' strate the enhancement of dopamine turnover (2) and decrease in dopamine D 2 receptor binding in vivo (3) by R-THBP injected peripherally. These results are consistent with our hypothesis described avove, In the present study, the autistic patients carefully selected from their data of R-THBP level in the cerebrospinal fluid were recruited to receive the R-THBP therapy and they were examined by PET before and just after the treatment according to the rules of Authorities of Drugs, Radioisotope Committee, and Ethical Committee for clinical studies. PET studies were performed one day befor the start of R-THBP ingestion for 12 weeks (3 mg/kg /day per os) and a day after cessation of treatment. In each occasion, regional cerebral blood flow (rCBF), dopamine turnover, and dopamine D 2 receptor binding in vivo were investigated by use of H 2 While numerous studies have now demonstrated that tetrahydrobiopterin (BH4) is essential for nitric oxide synthase catalyzed oxidation of L-arginine to L-citrulline and nitric oxide, its role in this complex reaction still remains ill defined. Tetrahydrobiopterin biosynthesis has been proposed to be an accessible pharmacological target in attempts to inhibit overproduction of nitric oxide which has been implicated in pathological and neurotoxic symptoms of septic shock as well as in some infectious diseases.
We have investigated the effect of depleting intracellular BH4 on the production of nitric oxide in the murine macrophage cell line, RA W264. Nitric oxide synthase has a very high affinity for BH4 and more than 90% must be removed before nitric oxide production is significantly reduced. However, trunover of BH4 in macrophages is extremely rapid suggesting that inhibitors of BH4 biosynthesis could be effective in vivo in reducing nitric oxide levels even at relatively low doses. Since purified nitric oxide synthase contains stoichiometric amounts of tightly bound BH", we have also now investigated the possibility that BH4 might playa regulatory role in transcription or translation of nitric oxide synthase. By Northern blot analyses, we have found that inducible nitric oxide synthase mRNA levels are not affected by inhibitors of BH4 biosynthesis. Furthermore, levels of nitric oxide synthase protein are also unaffected. However, nitric oxide synthase activity measured in vitro is very low in BH4-depleted cells and is not increased after preincubation with BH4, These results suggest that an alteration may occur to the nitric oxide synthase molecule after it is synthesized in the absence of BH4 rendering it irreversibly inactive. We previously reported that (6R)-5,6,7,8-tetrahydro-L-biopterin (R-THBP) has a unique activity for nitric oxide (NO) action to soluble guanylate cyclase (sGC) and conclude that it may be due to the stabilization of NO by R-THBPll. To elucidate the further biochemical mechanism of R-THBP, we studied superoxide disumutase (SOD) activity of R-THBP and this analogues in vitro. SOD enhanced the activation of sGC in a condition where NO was generated from NO-donor or NO synthase (NOS) was activated by calcium ion. The effect of R-THBP on sGC activation was seen in a similar manner to that of SOD. In the next study, we showed R-THBP itself possessed an SOD activity, and enhanced the activity in a low concentration (below 1 ~), which was compatible with the data of our previous reports. Other derivatives, except for tetrahydro-form, had little SOD-like activity. In the study using rat vascular smooth muscle cells (VSMC), which posess sGC activity but no NOS activity and no messenger RNA for inducible NOS, R-THBP enhanced sodium nitroprusside but not sodium nitrite action to sGc. These results clearly show that redox form of biopterin has an SOD-like activity. which is able to stabilize NO against super oxide, and relates to sGC activity distinct from activation of NOS. In addition, we also would like to discuss the cloning of rat NOS cDNA in the VSMC used through this study.
1) Nunokawa, Y. et al. Arch. Biochem. Biophys. (1992) and immunohistochemical studies 3 demonstrate that No synthase is expressed in the supraoptic nucleus of the rat hypothalamus, one of the control centers for food intake. These data implicate that NO produced in the brain is involved in the regulation of food intake. To test this hypothesis, we examined the effects of intracerebroventricular (i.c.v) injection of L-arginine (a substrate of NO synthase), 6R-tetrahydrobiopterin (6R-BH4; a cofactor for NO synthase) and N-monomethyl-L-arginine (L-NMMA; an inhibitor of NO synthase) on food intake of male Wistar rats. Two groups of rats were used: one group was allowed free access to food and water (satiated rats), and the other was deprived of food but not water for 24 or 72 h (starved rats). Food intake in both groups was represented by the amount of food consumed for 60 min between 9: 00 and 10: 00 am. Following food deprivation for 24 or 72 h (starved rats), food intake increased to 8-hold of that of satiated rats. The increase in food intake in the starved rats was partially suppressed by prior administration of L-NMMA In the starved rats, plasma levels of arginine, which were measured by HPLC with fluorescence detection, were unchanged in comparison with those in satiated rats, but arginine levels in the brain were reduced to 50%, indicating that consumption of arginine (as a substrate of NO synthase) is enhanced in the brain of the starved rats. In satiated rats, administration of L-arginine enhanced food intake to 200010 of the control value, but the enhancement was completely eliminated by pretreatment with L-NMMA Food intake in the satiated rats was also stimulated by administration of 6R-B~: the effect was additive with that of L-arginine. These data present evidence that NO generated in the brain is an endogenous regulator of food intake. Tetrahydrobiopterin (BH4) deficiency, a variant of hyperphenyl-alaninemia, may be caused by a defect in one of the following enzymes: GTP cyclohydro-lase I (GTPCH; E.C 3.5.4.16), 6-pyruvoyl-tetrahydropterin synthase (PTPS; E.C 4.6.1.10), or dihydropteridine reductase (DHPR; E.C 1.6.99.7). The first two enzymes are involved in the biosynthesis of BH4, the last one in its regeneration. "Primapterinuria" due to deficiency of pterin-4a-carbinolamine (pC D) is a transient condition with respect to hyperphenylalaninema. Although these diseases are rare (2-3% of all hyperphenylalaninemias) early detection by selective screening is essential for the treatment and outcome. BH4 deficiencies are very heterogeneous ranging from mild forms requiring only marginal if any treatment to severe forms which are in some cases very difficult to treat. Generally, one should distinguish between typical and atypical form depending on the need to treat the patient. In the typical form neurotransmitter biosynthesis has to be restored by substitution with the precursors L-Dopa and 5-hydroxy-tryptophan in addition to control of hyperphenylalaninemia by diet or BH4 administration. The only way to distinguish between these two forms is by evaluation of the CSF pterins and neurotransmitters. However, some patients with the atypical form were in the past designated as peripheral or partial PTPS deficient. Althoug they do not require substitution with neurotransmitters they actually need correction of hyperphenylalaninemia. In contrast, in mild forms of DHPR deficiency without hyperphenylalaninemia only the serotonin turnover is disturbed and treatment is only preventive. Furthermore, the atypical (peripheral) form may change . with development to the typical (severe) form as documented in two patients. The intermediate type of PTPS deficiency was described in another patient showing the biochemical features of partial PTPS deficiency but, after withdrawal of BH4, the clinical signs of severe PTPS deficiency. Evaluation of the international database with over 260 patients with BH4 deficiency (158 PTPS, 83 DHPR, 9 GT-PCH, 10 PCD deficiencies and 10 unknown) will be discussed with respect to the classification, treatment and outcome. The cerebellum is involved in various forms of motor learning throughout the animal kingdom. The vestibulo-ocular reflex (VOR) is a compensatory eye movement which stabilize images when the head moves. The VOR is tested by a sinusoidal oscillation of the head in darkness and its dynamics (VOR gain) is evaluated by measuring the movement of eye vs. the movement of the head. The VOR gain exhibits a marked adaptability by sustained visualvestibular interactions almost in all vertebrates, which is sqpposed to be an elementary model of cerebellar motor learning. Several lines of experiments using rabbits or monkeys consistently indicate that a particular group of neurons (Purkinje cells) in the cerebellar flocculus mediate an essential role of the learninp-of the VOR gain. In order to evaluate the e~cts of pteridine compound on the cerebellar functions, acute effects of the R-THBP (10 mglkg, i.m. injection) on the VOR gain were examined in alert pigmented rabbits. After injections of the R-THBP, the VOR gain increased by 30%, which lasted for 1-2h. This increase of the VOR gain was occluded by the learning of the VOR with the combined visual-vestibular interactions. Furthermore, after the lesions the cerebellar flocculus, the injection of R-THBP no longer induced an increase of the VOR gain. These experimental obsetvations suggest that the effects of the R-THBP on the VOR gain may be mediated in the cerebellum or cerebellar-related neuronal tissues. Several possible hypothesis will be discussed which may account for these effects of R-THBP on the cerebellar motor learning m echanism. Tetrahydrobiopterin (BR.) Therapy for 6-Pyruvoyl-tetrahydropterin Synthase Deficiency Haruo Shintaku l , Takuji Imamura l , Tatsuo Nakajima 2 , Yoshitomo Sawada 3 , Yutaka Hase 4 , Toshiaki Oura 5 , and Gen Isshiki Background and Methods. Biopterin is synthesized de novo through enzymatic steps and its vitaminlike effectiveness has considered negative. On the other hand, it is previously reported that higher concentration of biopterin was present in human milk than in commercial milk formulas and those reports suggest that breast-fed infants take more supply of biopterin than foumula-fed infants. We conducted two studies to determine the effect of the difference in dietary supply of biopterin. In the first study, we measured the bopterin levels of serum and urine in breast-fed and formula-fed infants. In the second study, we had two groups of guinea-pig fed regulaly mixed with biopterin compatible to concentration of human milk and commercial milk formulas. After feeding two weeks, we measured serum biopterin levels in the both groups. Analysis of total biopterin was done by reverse-phase high pressure liquid chromatography.
Results. There was no significant difference in the biopterin levels of serum and urine between breastfed and formula-fed infants. And there was no significant difference in the serum biopterin levels between two groups of guinea-pig.
Conclusions. The difference of the dietary supply of biopterin in infans brought no significant effect on the serum and urinary levels of biopterin. Several reports have shown an increase in biopterin (Bp) concentrations in human milk and have suggested this may play some role in physiological functions. In this study we examined the total Bp concentrations in human milk and serum of postpartum babies.
Methods: The total Bp in the milk and serum was analyzed according to a slight modification of the method described by Fukushima and Nixon, including an acid-oxidation step; 0.5 ml of milk (0.2 ml, sera in brackets) was oxidized and deproteinized by 2 m1 (0.28 ml) of 0.9% iodine and 1.8% KI in 2N HC} and 2 ml (0.06 ml) of 30% TCA After standing for 60 min in room temperature, the mixture was centrifused and the excess iodene reduced by the addition of ascorbic acid powder. The solution was then neutralized with 5N NaOH and analyzed by HPLC (ex. 370,em.450). The solvent was O.oI5 M KPB (pH 6.0).
Materials: 131 milk samples obtained from 19 women (4-12 daily samples/woman) and the intake of each babies was recorded. Samples ranged from 1st to 13th day postpartum. An additional 10 samples of milk aged 14 days to 10 months, were also collected. The 18 serum samples were taken from 3-5 day old babies during regular pediatric checks. These samples were stored at -20°C until assayed. The results were calculated without correction for recovery.
Results: Using fluorescence detection and HPLC, the peak height of fluorescence was found to be proportional to the amounts of Bp and tetrahydrobiopterin (BH4), as listed below. Total Bp level in the milk samples was 148 nM on the 1st day (n = 14), 487 nM on the 3rd day (n= 18), 779 nM on the 5th day (n= lO), 911 nM on the 7th day (n=9), and 348 nM from 14th day to 10th month (n= lO). The average total Bp in the sera was 10.0 nM. The total Bp intake of the babies during the day prior to · the collection of blood samples did not correlate with the total Bp level of the serum.
Pteridines in Human Skin
Yoshitomo Sawada l , Hamo Shintaku 2 , Takuji Imamura 2 , Yutaka Hase 3 , Toshiaki Oura 4 , and Gen Isshiki 2 IDept. of Pediatr., Osaka City General Hospital, Osaka 534, Japan, and 2Dept. of Pediar., Osaka City University Medical School, Osaka 545, Japan, and 3Dept. of Pediatr., Kita Citizens' Hospital, Osaka 554, Japan, and 40saka Municipal Rehabilitation Center for the Disabled, Osaka 547, Japan.
We measured the concentration of neopterin and biopterin in human hair. Hair was sonicated before iodine oxidation by Fukushima-Nixon's method. The concentraitons of neopterin and biopterin in a hair on the head were 0.30± 0.17 adn 1.2± 0.32 pmol/W min in length, respectively, in controls (n= 3).
The neopterin and biopterin levels in a hair of a tetrahydrobiopterin (BH 4 )-deficient patient were 0.9 and 0.04 pmol/lO mm in length, respectively.
We also confirmed that pteridines were contained in human hair follicles, sebacious glands, pubic hair, axillary hair, and lanugo hair. We don't know the role of pteridines in human hair yet. But measuring of pteridines in human hair may help diagnose BH4 -deficient patients or detect their heterozygotes. Since the first description of nitric oxide synthase (NOS) purified from murine macrophages (Marletta et ai., 1989; Stuehr et ai., 1989) , tetrahydrobiopterin (BH4) has been stated to be required as a cofactor. Meanwhile NOS has been purified and cloned from many systems including brain, hepatocytes, smooth muscle cells, and endothelial cells. NOS turned out to be present in two isoforms, a calcium!calmodulin dependent constitutive form (cNOS), and a calcium independent form inducible by cytokines and endotoxin (iNOS). Both, cNOS and iNOS, require stoichiometric amounts of BH4 for full activity. Nitric oxide (NO) seems to playa crucial role in the regulation of the vascular tone, and might be responsible for cytokine and endotoxin-induced hypotension. Suppression of NO overproduction down to physiological levels by inhibition of co-induced BH4 biosynthesis could therefore be a relatively selective therapeutic approach for conditions such as septic shock. Inhibitors of sepiapterin reductase, which catalyzes the terminal reactions of the BH4 biosynthesis, will be most specific by depletion of BH4 without interfering with the synthesis of the dihydroneopterin triphosphate and pyruvoyltetrahydropterin precursors. To test for this hypothesis we used the sepiapterin reductase inhibitors Dicumarol (originally described as equipotent to N-acetylserotonin by S. Katoh) and its derivative, phenprocoumon (Marcoumar®). In murine macrophages activated with IFNy (50 U/ml) or with combined IFN-y and endotoxin (LPS, 200 ng/ml), 50 ~ phenprocoumon suppressed induction of NO synthesis down to the level of unstimulated control cells. In murine endothelial cells stimulated either by cytokines (lFN-y, 100 U Imol; TNF-a, 100 U/ml) or LPS (1 Ilg/ml), phenprocoumon and Dicumarol suppressed NO synthesis by 70 and 100%, respectively. This was reflected by very low intracellula BH4 levels in the activated cells. NO synthesis suppressed in activated endothelial cells by Dicumarol or Marcoumar® could be fully restored by addition of exogenous BH4, but not by sepiapterin. These results confirm the dependence of induced NO synthesis on the BH4 cofactor as well as the selectivity of the inhibitors. These findings also encourage further studies of BH4 synthesis inhibitors for therapeutic interventions in NO-mediated changes of vascular tone. 6-Pyruvoyl-tetrahydropterin synthase (PTPS) is the rate limiting enzyme in the synthesis of human tetrahydrobiopterin, a cofacotor for several hydroxylases involved in catecholamine and serotonin biosynthesis. The human liver cDNA encoding the 16 kDa subunit of PTPS was expressed as maltose binding (MBP)-PTPS fusion protein. After cleavage from the MBP fusion protein, the human PTPS was purified to homogeneity. Apparent ~ for the substrate dihydroneopterin triphosphate (8.5 for human PTPS), pI (4.6) and heat stability of the recombinant enzyme was similar to the native enzyme.
It is known that PTPS is a Mg2+ -dependent enzyme. When Mg2+ was replaced by several transition state metals such as Fe2+ and Mn H we observed an up to two fold enhanced activity compared to the activity in presence of Mg2+.
Modification under non-reducing conditions of the two cysteine residues of human PTPS by Nethylpyridine resulted in a 95% loss of enzymatic activity. This demonstrates that the two cysteines are not linked by disulfide bridges but rather 'involved in catalysis. To point out these results we designed two altered enzymes by site directed mutagenesis where the two cysteines were replaced by alanine. We could show that the replacement of the cysteine at amino acid position 10 had no influence on the enzymatic activity, whereby the replacement of the conserved cysteine at amino acid position 43 in human and 42 in rat PTPS, respectively, led to a complete inactivation of PTPS.
Long-Tenn Therapeutic Trial for a PIPS Deficient Patient: The Benefit of BlL Monotherapy Keiko Tanaka, Nobuya Fujita, Hiroshi Kondo, Tadashi Nakajima, Makoto Yoneda, Shoji Tsuji, and Tadashi Miyatake ' Dept. Neurology, Brain Research Institute, Niigata University, Niigata 951, Japan, 'Dept. Neurology, Tokyo Medical and Dental University, Tokyo, Japan We had reported a 27 years old man with pyruvoyltetrahydropterine synthetase (PTPS) deficiency, who showed mild mental retardation, rigidospasticity, dystonia, bradykinesia with marked diurnal fluctuation of symptoms. He has received various therapeutic trials since then. We previously concluded that BH4 with small amount of L-Dopa was the best choice of treatment after several combinations of therapeutic trial. The brief summary of the results is. I) L-Dopa monotherapy improved his ri-gidospasticity, S-Hydroxy triptophan (SHTP) impro
